4//SEC Filing
Valeant Pharmaceuticals International, Inc. 4
Accession 0000885590-14-000069
$BHCCIK 0000885590operating
Filed
Oct 6, 8:00 PM ET
Accepted
Oct 7, 4:19 PM ET
Size
9.3 KB
Accession
0000885590-14-000069
Insider Transaction Report
Form 4
Schiller Howard Bradley
EVP and CFO
Transactions
- Exercise/Conversion
Common Stock, no par value
2014-10-03+22,500→ 285,500 total - Tax Payment
Common Stock, no par value
2014-10-03−11,786→ 273,714 total - Exercise/Conversion
Restricted Share Units
2014-10-03−22,500→ 67,500 total→ Common Stock (22,500 underlying)
Footnotes (2)
- [F1]This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $42.70 starting on December 1, 2011 and the average stock price for the 20 trading days starting on each measurement dates: 25% on September 1, 2014, 50% on December 1, 2014 and 25% on March 1, 2015. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels.
- [F2]This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Performance Share Units.
Documents
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000885590
Filing Metadata
- Form type
- 4
- Filed
- Oct 6, 8:00 PM ET
- Accepted
- Oct 7, 4:19 PM ET
- Size
- 9.3 KB